Inactive Instrument

Highlights Catabasis Pharmaceuticals Inc Nasdaq

Equities

US14875P1075

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Wedbush Raises Astria Therapeutics' PT to $22 From $17 After Reporting Top-Line Phase 1/2 ALPHA-STAR Results for STAR-0215 Program; Maintains Outperform Rating	Mar. 26	MT
Astria Therapeutics, Inc. Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE	Mar. 25	CI
Astria Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 04	CI
Astria Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Astria Therapeutics, Inc. Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting	Nov. 10	CI
Glenmark Pharma Unit Licenses Antibody Portfolio to Astria Therapeutics	23-10-12	MT
Ichnos Sciences Enters Licensing Agreement for Ox40 Antibody Portfolio with Astria Therapeutics	23-10-11	CI
Astria Therapeutics, Inc. Announces Exclusive Worldwide License Agreement with Ichnos Sciences for Ox40 Portfolio	23-10-11	CI
Astria Therapeutics, Inc. Announces Publication of Star-0215 Preclinical Data in the Journal of Pharmacology and Experimental Therapeutics	23-08-31	CI
Astria Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Astria Therapeutics' Genetic Disorder Drug Candidate Granted FDA Fast-Track Designation	23-07-20	MT
Astria Therapeutics, Inc. Receives Fast Track Designation for Star-0215 for the Treatment of Hereditary Angioedema	23-07-20	CI
Astria Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Astria Therapeutics Q4 Loss Narrows	23-03-22	MT
Astria Therapeutics, Inc. Initiates ALPHA-STAR Phase 1b/2 Clinical Trial of STAR-0215 in People with HAE	23-02-08	CI
Astria Therapeutics, Inc. Announces Positive Preliminary Results from the Phase 1A Clinical Trial of Star-0215 in Healthy Subjects	22-12-15	CI
Earnings Flash (ATXS) ASTRIA THERAPEUTICS Reports Q3 Loss $-0.87	22-11-10	MT
Astria Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Astria Therapeutics, Inc. to Present STAR-0215 Modeling and Simulation Data at the 2022 American College of Allergy, Asthma and Immunology Annual Meeting	22-11-07	CI
Earnings Flash (ATXS) ASTRIA THERAPEUTICS Reports Q2 Loss $-0.86	22-08-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Catabasis Pharmaceuticals Inc Nasdaq

Equities

US14875P1075

Highlights

Filters